SARS-CoV-2, daha önce insan ve hayvanlardan izole edilmemiş yeni bir koronavirüs [coronavirus (CoV)] suşudur. İnsanlarda, COVID19 hastalığına yol açar. COVID-19, sistemik bir hastalıktır. Bazı COVID-19 hastaları, hastalığı ağır geçirir ve bu esnada yoğun bakım ünitesi (YBÜ)ne alınırlar. Bu hastalarda, SARS-CoV-2 virüsünün neden olduğu sitokin fırtınası hem 7 günden önceki erken dönemde hem de 2. dalga olarak 7-10. günlerde gelişebilir. Sitokin fırtınası, bu hastalığın gidişatını kötüleştirir. Mutlaka tedavi edilmelidir. Hastalar, SARS-CoV2 virüsünü bertaraf edebilmek için virüse karşı etkin antikor üretirler. Tedavide, COVID-19 hastalığını atlatan uygun donörlerden immün plazma alınır ve hastalığı ağır atlatan hastalara verilebilir. Bu olgu serisinde, SARS-CoV-2 virüsüyle enfekte olmuş, YBÜ'ye alınan 5'i vefat eden, 7 COVID-19 hastasının tedavisini ve bu tedaviye immün plazmanın etkilerini sunmayı amaçladık.
Anahtar Kelimeler: SARS-CoV-2; COVID-19; sitokin fırtınası; immün plazma tedavisi
SARS-CoV-2 is a new strain of coronavirus (CoV) not previously isolated from humans and animals. It causes COVID-19 disease in humans. COVID-19 is a systemic disease. Some COVID19 patients suffer from the disease and are taken to the intensive care unit. In these patients, the cytokine storm caused by the SARS-CoV2 virus is both early in the 7 days and 7-10 as the second wave may develop in days. Cytokine storm worsens the course of this disease. It must be treated. Patients produce anti-virus antibodies to eliminate the SARS-CoV-2 virus. In treatment, immune plasma is taken from suitable donors that survive COVID-19 disease and can be given to these patients who have suffer from the disease. In this case series, we aimed to treat the 7 COVID-19 patients with 5 ex who were taken to the intensive care unit infected with the SARS-CoV-2 virus and the effects of immune plasma to this treatment.
Keywords: SARS-CoV-2; COVID-19; cytokine storm; immune plasma therapy
- Yao Q, Wang P, Wang X, Qie G, Meng M, Tong X, et al. A retrospective study of risk factors for severe acute respiratory syndrome coronavirus 2 infections in hospitalized adult patients. Pol Arch Intern Med. 2020;130(5):390-9.[Crossref] [PubMed]
- Wang LX, Chen X, Jia M, Wang S, Shen J. Arthritis of large joints shown as a rare clinical feature of cytokine release syndrome after chimeric antigen receptor T cell therapy: a case report. Medicine (Baltimore). 2018;97(16):e0455.[Crossref] [PubMed] [PMC]
- Geng YJ, Wei ZY, Qian HY, Huang J, Lodato R, Castriotta RJ. Pathophysiological characteristics and therapeutic approaches for pulmonary injury and cardiovascular complications of coronavirus disease 2019. Cardiovasc Pathol. 2020;47:107228.[Crossref] [PubMed] [PMC]
- Lawless RA, Holcomb JB. Plasma transfusion. Trauma Induced Coagulopathy. 2015:323-37.[Crossref] [PMC]
- Tanne JH. Covid-19: FDA approves use of convalescent plasma to treat critically ill patients. BMJ. 2020;368:m1256.[Crossref] [PubMed]
- Çelebi H. [Plasma products and transfusion indications]. Turkiye Klinikleri J Int Med Sci. 2007;3(36):62-4. [Link]
- Sullivan HC, Roback JD. Convalescent plasma: therapeutic hope or hopeless strategy in the SARS-CoV-2 pandemic. Transfus Med Rev. 2020;34(3):145-50.[Crossref] [PubMed] [PMC]
- Devasenapathy N, Ye Z, Loeb M, Fang F, Najafabadi BT, Xiao Y, et al. Efficacy and safety of convalescent plasma for severe COVID-19 based on evidence in other severe respiratory viral infections: a systematic review and meta-analysis. CMAJ. 2020;192(27):E745-55.[Crossref] [PubMed]
- Tiberghien P, de Lamballerie X, Morel P, Gallian P, Lacombe K, Yazdanpanah Y. Collecting and evaluating convalescent plasma for COVID-19 treatment: why and how? Vox Sang. 2020;115(6):488-94.[Crossref] [PubMed]
- Roback JD, Guarner J. Convalescent plasma to treat COVID-19: possibilities and challenges. JAMA. 2020;323(16):1561-2.[Crossref] [PubMed]
- Syal K. COVID-19: Herd immunity and convalescent plasma transfer therapy. J Med Virol. 2020;92(9):1380-2.[Crossref] [PubMed] [PMC]
- Rajendran K, Krishnasamy N, Rangarajan J, Rathinam J, Natarajan M, Ramachandran A. Convalescent plasma transfusion for the treatment of COVID-19: systematic review. J Med Virol. 2020;92(9):1475-83.[Crossref] [PubMed] [PMC]
- Duan K, Liu B, Li C, Zhang H, Yu T, Qu J, et al. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proc Natl Acad Sci USA. 2020;117(17):9490-6.[Crossref] [PubMed] [PMC]
- Rojas M, Rodríguez Y, Monsalve DM, Acosta-Ampudia Y, Camacho B, Gallo JE, et al. Convalescent plasma in Covid-19: Possible mechanisms of action. Autoimmun Rev. 2020;19(7):102554.[Crossref] [PubMed] [PMC]
- Li L, Zhang W, Hu Y, Tong X, Zheng S, Yang J, et al. Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: a randomized clinical trial. JAMA. 2020;324(5):460-70.[Crossref] [PubMed] [PMC]
- Felsenstein S, Herbert JA, McNamara PS, Hedrich CM. COVID-19: immunology and treatment options. Clin Immunol. 2020;215:108448.[Crossref] [PubMed] [PMC]
- Brown BL, McCullough J. Treatment for emerging viruses: convalescent plasma and COVID-19. Transfus Apher Sci. 2020;59(3):102790.[Crossref] [PubMed] [PMC]
- Shen C, Wang Z, Zhao F, Yang Y, Li J, Yuan J, et al. Treatment of 5 critically Ill patients with COVID-19 with convalescent plasma. JAMA. 2020;323(16):1582-9.[Crossref] [PubMed] [PMC]
- Erkurt MA, Sarici A, Berber İ, Kuku İ, Kaya E, Özgül M. Life-saving effect of convalescent plasma treatment in covid-19 disease: Clinical trial from eastern Anatolia. Transfus Apher Sci. 2020;59(5):102867.[Crossref] [PubMed] [PMC]
.: Process List